A controlled trial with vasopressin analogue (DGAW) on cognitive recovery immediately after head trauma

Nicolaas J. Bohnen*, Albert Twijnstra, Jellemer Jolles

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    72 Downloads (Pure)


    Recent evidence suggests that the vasopressin analogue desglycinamide-arginine8-vasopressin (DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treatment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matched-pairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients.
    Original languageEnglish
    Pages (from-to)103-106
    Number of pages4
    Issue number1
    Publication statusPublished - 1 Jan 1993

    Cite this